PATIENTS with brain metastases and Type 2 diabetes using glucagon-like peptide-1 receptor agonists (GLP-1RA) have a near 40% lower risk of death over 3 years compared with nonusers, a 2026 retrospective cohort study has found.
Comorbid Type 2 Diabetes Can Worsen Brain Metastases Outcomes
Brain metastases are secondary tumours that form in the brain when cancer cells spread from their original site.
They are associated with high rates of morbidity and mortality.
Comorbid Type 2 diabetes can worsen the relevant outcomes through metabolic and inflammatory pathways, which GLP-1RAs could combat through their potential neuroprotective and anti-inflammatory effects.
GLP-1RAs Were Associated with a 37% Lower Risk of Death
Researchers identified 850 adult patients with brain metastases and Type 2 diabetes between 1 January…